Skip to content
Menu

Erasca, Inc. ERAS

Full chart Compare
Set alert

Price alert · ERAS

All alert types
13.61 USD -0.61 (-4.29%)

Regular-session close

13.61 0.00 0.00%

After hours · Nov 20, 4:51 PM ET

13.13 Day range 14.30
2.75 52-week range 24.28
YTD
+265.86%
1 year
+389.57%

5D -2.16 (-13.70%)

131415MonTueWedThuFri13.61
Market cap
4.78B
EPS (ttm)
-0.97
Shares out
350.96M
Forward P/E
-17.36
YTD return
+265.86%
1-year return
+389.57%
50-day average
14.81
200-day average
15.33
Enterprise value
4.39B
Price / book
5.20
Volume
11.07M
Avg volume
5.14M
Open
13.13
Previous close
14.22
Day's range
13.13 – 14.30
52-week range
2.75 – 24.28
Beta
0.65
Analysts
Buy
Price target
25.10 (+84.4%)
Earnings date
Mar 11, 2027

Key statistics

Free cash flow
-207.85M
Total cash
643.70M
Total debt
43.41M
Return on equity
-48.70%
Short % of float
11.74%

Fundamental scorecard

3 of 25 checks passed on ERAS’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ERAS Revenue — quarterly 0
ERAS Net income — quarterly -51.33M
ERAS EPS — quarterly -0.15

Earnings

ERAS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 11, 2027Dec 30, 2026-0.15———
Nov 12, 2026Sep 30, 2026-0.13013-0.15-0.02-15.27%
Aug 12, 2026Jun 30, 2026-0.11137-0.14-0.03-25.71%
May 11, 2026Mar 31, 2026-0.11152-0.60-0.49-438.02%
Mar 12, 2026Dec 31, 2025-0.11-0.10+0.01+9.09%
Nov 12, 2025Sep 30, 2025-0.11-0.110.000.00%

Upgrades / downgrades

ERAS analyst upgrades and downgrades
DateFirmActionFromTo
Aug 14, 2026B of A SecuritiesmainNeutralNeutral
Aug 13, 2026GuggenheimmainBuyBuy
Aug 12, 2026HC Wainwright & Co.mainBuyBuy
Jul 20, 2026Morgan StanleymainEqual-WeightEqual-Weight
Jul 14, 2026B of A SecuritiesmainNeutralNeutral
Jun 4, 2026B of A SecuritiesupUnderperformNeutral

About Erasca, Inc.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015; and clinical collaboration with Bristol Myers Squibb to evaluate ERAS-0015 in clinical study with Navlimetostat. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
erasca.com

News

Your note

Sign in to keep a note on ERAS — it syncs with the Stock Master app.

Insider holders

ERAS insider holders
InsiderRelationLatest transactionDateShares held
GARNER EBUN SOfficerConversion of Exercise of derivative securityMar 31, 202625,076
MORRIS SHANNON R. M.D., PH.D.OfficerConversion of Exercise of derivative securityMar 3, 20260
MULTANI PRATIK SDirectorStock GiftMay 22, 2025172,866

Institution ownership

ERAS institution ownership
Holder% heldSharesValueReported
Frazier Life Sciences Management, L.P. 8.40%29,475,188401.16MSep 29, 2026
Blackrock Inc.6.76%23,736,078323.05MSep 29, 2026
RTW Investments LP6.40%22,446,754305.50MSep 29, 2026
Venrock Adviser, LLC5.72%20,089,932273.42MSep 29, 2026
T. Rowe Price Investment Management, Inc.4.90%17,192,148233.99MSep 29, 2026
Vanguard Capital Management LLC3.96%13,905,796189.26MSep 29, 2026

Fund ownership

ERAS fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.39%8,384,454114.11MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.39%8,381,324114.07MSep 29, 2026
T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App1.98%6,954,60094.65MJun 29, 2026
SmallCap World Fund Inc1.96%6,886,44693.72MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF1.63%5,734,87578.05MSep 29, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.0.95%3,334,92145.39MJun 29, 2026